Anelixis Therapeutics is a clinical stage development company located in Cambridge, Massachusetts. Anelixis has a portfolio of antibodies blocking CD40L activity. Anelixis is developing its lead compound, AT-1501, in Amyotrophic Lateral Sclerosis, organ and cellular transplantation, and autoimmunity.
Anelixis Therapeutics was formed in 2013 and is a for-profit subsidiary of ALS Therapy Development Institute (ALSTDI, www.als.net), a nonprofit biotechnology organization dedicated to developing effective treatments for ALS
The development of AT-1501 has been funded by the philanthropic support of hundreds of ALS patients and families supporting research at ALS TDI, Augie's Quest, as well as peer-reviewed grants from ALS One, ALS Finding a Cure, and the ALS Association.